Based on the fact that induction of apoptosis is one of the most important strategies in anti-tumor therapy [40] and that both 17-AAG and MKT-077 exert their anti-cancer effects in a p53-dependent manner, we proposed that combinations of HSP90 inhibitors and the GRP75 inhibitors could be significantly and synergistically effective in HCC therapy. The gene discussed is TP53; the disease is cancer.